Currently, Immune checkpoint inhibitors (ICIs), primarily PD-1/PD-L1 blockers have shown remarkable success in treating a variety of malignancies, and their efficacy in many clinical trials has advanced the treatment of CRC, gastric cancer (GC), and other GI tumors [4-7]. The gene discussed is CD274; the disease is colorectal carcinoma.